Jacqualyn A Fouse is Director of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 140,784 shares of AGIO, which is worth approximately $8.1 Million. The most recent transaction as insider was on Jun 13, 2024, when has been sold 3,388 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 141K
0% 3M change
31.62% 12M change
Total Value Held $8.1 Million

JACQUALYN A FOUSE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 13 2024
BUY
Exercise of conversion of derivative security
-
3,388 Added 2.35%
140,784 Common Stock
Apr 10 2024
SELL
Open market or private sale
$214,642 $27.55 p/Share
7,791 Reduced 5.37%
137,396 Common Stock
Apr 08 2024
BUY
Exercise of conversion of derivative security
-
15,934 Added 9.89%
145,187 Common Stock
Jan 24 2024
SELL
Open market or private sale
$232,024 $21.64 p/Share
10,722 Reduced 7.66%
129,253 Common Stock
Jan 20 2024
BUY
Exercise of conversion of derivative security
-
23,900 Added 14.58%
139,975 Common Stock
Jan 09 2024
SELL
Open market or private sale
$192,909 $22.99 p/Share
8,391 Reduced 6.74%
116,075 Common Stock
Jan 05 2024
BUY
Exercise of conversion of derivative security
-
17,500 Added 12.33%
124,466 Common Stock
Jun 30 2023
SELL
Open market or private sale
$303,962 $28.36 p/Share
10,718 Reduced 9.11%
106,966 Common Stock
Jun 28 2023
BUY
Exercise of conversion of derivative security
-
23,900 Added 16.88%
117,684 Common Stock
Apr 12 2023
SELL
Payment of exercise price or tax liability
$101,006 $21.35 p/Share
4,731 Reduced 4.8%
93,784 Common Stock
Apr 08 2023
BUY
Exercise of conversion of derivative security
-
15,933 Added 13.92%
98,515 Common Stock
Feb 16 2023
SELL
Payment of exercise price or tax liability
$105,463 $28.91 p/Share
3,648 Reduced 4.23%
82,582 Common Stock
Feb 14 2023
BUY
Exercise of conversion of derivative security
-
11,333 Added 11.62%
86,230 Common Stock
Feb 22 2022
SELL
Payment of exercise price or tax liability
$106,840 $29.08 p/Share
3,674 Reduced 4.68%
74,897 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
12,379 Added 13.61%
78,571 Common Stock
Feb 14 2022
SELL
Payment of exercise price or tax liability
$106,902 $30.5 p/Share
3,505 Reduced 5.03%
66,192 Common Stock
Feb 14 2022
BUY
Exercise of conversion of derivative security
-
11,334 Added 13.99%
69,697 Common Stock
Feb 14 2021
SELL
Payment of exercise price or tax liability
-
3,398 Reduced 5.5%
58,363 Common Stock
Feb 14 2021
BUY
Exercise of conversion of derivative security
-
11,333 Added 15.5%
61,761 Common Stock

Also insider at

INCY
INCYTE CORP Healthcare
JAF

Jacqualyn A Fouse

Director
Wilmington, DE

Track Institutional and Insider Activities on AGIO

Follow AGIOS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO